Efficacy and safety of using eslicarbazepine in treating focal epilepsy in clinical practice (based on international Euro-Esli study and personal experience)
https://doi.org/10.17749/2077-8333/epi.par.con.2020.048
Abstract
The latest data on the eslicarbazepine (ESL) efficacy, tolerability and safety in treatment of focal epilepsy are presented based on the results of the European study in clinical practice Euro-Esli that enrolled 2058 patients from 14 European centers, a detailed subgroup analysis, as well as our own data on the follow-up of 65 patients with focal epilepsy receiving ESL in monotherapy or combination therapy.
According to the Euro-Esli study, a 12-months follow-up allowed to conclude that therapy retention comprised 73.4%; percentage of responders was 75.6%, whereas proportion of patients with complete seizure cessation was 41.3 %. Regarding ESL efficacy it may be concluded that our personal data were comparable to those obtained during the international study Euro-Esli so that retention was 80%; percentage of responders was 75.4%, whereas seizure-free rate was 58.5%. As for the ESL safety profile our study demonstrated that adverse events (AEs) were registered at lower rate in as few as 21.5% of patients compared to 34% found in the Euro-Esli study. No unexpected serious AEs during the long-term follow-up period were documented in the both studies, which evidence about favorable ESL safety profile elderly patients, patients with comorbid intellectual and mental disorders as well as patients with post-stroke epilepsy.
About the Authors
I. A. Zhidkova
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Irina A. Zhidkova - MD, Dr Sci Med, PhD, Professor of the Department of Nervous Diseases.
20-1 Delegatskaya Str., Moscow 127473
V. A. Karlov
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Vladimir A. Karlov - Honored Scientist of the Russian Federation, Associate Member of the Russian Academy of Sciences, MD, Dr Sci Med; Professor of Chair of Neurology, Department of General Medicine, Evdokimov MS UMD; President of the Russian League Against Epilepsy (RLAE) - ILAE Russian Chapter, Scopus ID: 7103065003; RSCI SPIN-code: 2726-9790.
20-1 Delegatskaya Str., Moscow 127473
P. N. Vlasov
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Pavel N. Vlasov - MD, Dr Sci Med, Professor, Department of Nervous Diseases, Faculty of Medicine, Scopus ID: 7101688064; RSCI SPIN-code: 701071.
20-1 Delegatskaya Str., Moscow 127473
References
1. Karlov V.A. Epilepsy in children and adult females and males. Physicians manual. Second edition. Moscow. 2019; 893 p. (in Russ).
2. Ferreira J., Mestre T. Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. Expert Opin. Investig. Drugs. 2009; 18 (2): 221-229.
3. Vlasov P.N. Eslikarbazepin. Mekhanizm deistviya. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2015; Spetsvypusk: 2-4. (in Russ).
4. Instructions for medical use of the drug Exalief LP - 001263 dated 04.27.2017 (in Russ).
5. Zhidkova I.A., Karlov V.A., Vlasov P.N. Eslicarbazepine in the treatment of focal epilepsy. Zhurnal nevrologii i psikhiatrii im. Korsakova. 2018; 4: 140-145. (in Russ).
6. Shorvon S., Trinka E., Steinhoff B., Holtkamp M. et al. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies. J Neurol. 2017; 264: 421-431. https://doi.org/10.1007/s00415-016-8338-2.
7. Trinka E., Kowacs P., Ben-Menachem E., Elger C. et al. Safety and tolerability of eslicarbazepine acetate as monotherapy in patients with newly diagnosed partial-onset seizures. Epilepsia. 2016; 57 (Suppl 2): 186-187. https://doi.org/10.1111/epi.13609.
8. Villanueva V., Holtkamp M., Delanty N. et al. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures. J Neurol. 2017; 264: 2232-2248. https://doi.org/10.1007/s00415-017-8618-5.
9. Holtcamp M., Delanty N., Sales F., Serratosa J. et al. Eslicarbazepine acetate as monotherapy in clinical practice: outcomes from Euro-Esli. Acta Neurol Scand. 2019; 139 (1): 49-63.
10. Karlov V.A., Gyekht A.B., Guzeva V.I., Lipatova L.V, Bazilevich S.N., Mkrtchan V.R., Vlasov P.N., Zhidkova I.A., Mukhin K.Yu., Petrukhin A.S., Lebedeva A.V. Algorithms for mono- and polytherapy in clinical epileptology. Part 1. General principles for choosing pharmacotherapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016; 6: 109-114. https://doi.org/10.17116/jnevro201611661109-114. (in Russ).
11. Baulac M. Rational Conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 2003; 5: 125-132;
12. Brodie M., Sills G. Combining antiepileptic Drugs - Rational polytherapy? Seizure. 2011; 20 (5): 369-375.
13. Doherty C.P., Rheims S., Assenza G., Boero G., Chaves J., McMurray R., Villanueva V. Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: Clinical practice findings from the Euro-Esli study. J Neurol Sci. 2019 Jul 15; 402: 88-99. https://doi.org/10.1016/j.jns.2019.04.040.
14. Lawthom C., Bermejo P., Campos D., McMurray R, Villanueva V. Effectiveness and Safety/Tolerability of eslicarbazepine Acetate in Epilepsy Patients Aged > 60 Versus < 60 Years: A Subanalysis from the Euro-Esli Study. Neurol Ther. 2019; 8 (2): 491-504. https://doi.org/10.1007/s40120-019-0137-0.
15. Rocamora R. et al. Poster P0914 presented at the 32nd International Epilepsy Congress. Barcelona. 2-6 September 2017.
16. Chaves J., Sales F., Villanueva V., McMurrey R. et al. Efficacy, Safety and Tolerability of eslicarbazepine acetate in post-stroke Epilepsy: real-world evidence from the Euro-Esli study. Presented at the AES Annual Meeting 2018, New Orleans, USA. November 30 - December 4. 2018; 2: 465.
17. Karlov V.A. Clinical efficacy and safety of eslicarbazepine acetate (ESL) in monotherapy regimen and as an add-on therapy in focal epilepsy. 3rd Pan-Slavic Congress of Child Neurology and 21 Congress of Child Neurologists from Mediterranean. Dubrovnik, 2016. Book of abstracts: 10.
18. Avakyan G.N. Exalief: new perspectives in epilepsy treatment. Epilepsia i paroksizmal'nye sostoania / Epilepsy and Paroxysmal Conditions. 2015; Special issue: 18-19. (in Russ).
Review
For citations:
Zhidkova I.A., Karlov V.A., Vlasov P.N. Efficacy and safety of using eslicarbazepine in treating focal epilepsy in clinical practice (based on international Euro-Esli study and personal experience). Epilepsy and paroxysmal conditions. 2020;12(3):182-191. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2020.048
Views: 475
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
